- Home
- CSTL
as of 11-28-2025 12:54pm EST
$39.54
$0.40
-1.00%
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Chart Type:
Time Range:
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 661.7M | IPO Year: | 2019 |
| Target Price: | $38.67 | AVG Volume (30 days): | 588.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.59 - $40.61 | Next Earning Date: | 11-03-2025 |
| Revenue: | $343,530,000 | Revenue Growth: | 10.15% |
| Revenue Growth (this year): | -2.44% | Revenue Growth (next year): | -1.26% |
AI-Powered CSTL Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 70.07%
70.07%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Nov 25, 2025
Avg Cost/Share
$40.05
Shares
5,115
Total Value
$204,850.64
Owned After
45,822
SEC Form 4
Juvenal Tobin W
Sell
Chief Commercial Officer
CSTL Nov 20, 2025
Avg Cost/Share
$35.58
Shares
4,693
Total Value
$166,976.94
Owned After
84,595
SEC Form 4
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Nov 18, 2025
Avg Cost/Share
$34.02
Shares
2,678
Total Value
$91,105.56
Owned After
45,822
SEC Form 4
Juvenal Tobin W
Sell
Chief Commercial Officer
CSTL Nov 12, 2025
Avg Cost/Share
$35.40
Shares
200
Total Value
$7,080.00
Owned After
84,595
SEC Form 4
Juvenal Tobin W
Sell
Chief Commercial Officer
CSTL Nov 11, 2025
Avg Cost/Share
$35.39
Shares
500
Total Value
$17,695.00
Owned After
84,595
SEC Form 4
Oelschlager Kristen M
Sell
Chief Operating Officer
CSTL Nov 11, 2025
Avg Cost/Share
$35.10
Shares
18,932
Total Value
$664,513.20
Owned After
12,323
SEC Form 4
Stokes Frank
Sell
Chief Financial Officer
CSTL Nov 11, 2025
Avg Cost/Share
$35.08
Shares
5,388
Total Value
$189,011.04
Owned After
43,328
SEC Form 4
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Nov 5, 2025
Avg Cost/Share
$31.85
Shares
2,678
Total Value
$85,296.98
Owned After
45,822
SEC Form 4
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Nov 4, 2025
Avg Cost/Share
$30.77
Shares
6,695
Total Value
$203,781.88
Owned After
45,822
Oelschlager Kristen M
Sell
Chief Operating Officer
CSTL Oct 31, 2025
Avg Cost/Share
$25.04
Shares
12,678
Total Value
$317,457.12
Owned After
12,323
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Nov 25, 2025 | Sell | $40.05 | 5,115 | $204,850.64 | 45,822 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Nov 20, 2025 | Sell | $35.58 | 4,693 | $166,976.94 | 84,595 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Nov 18, 2025 | Sell | $34.02 | 2,678 | $91,105.56 | 45,822 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Nov 12, 2025 | Sell | $35.40 | 200 | $7,080.00 | 84,595 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Nov 11, 2025 | Sell | $35.39 | 500 | $17,695.00 | 84,595 | |
| Oelschlager Kristen M | CSTL | Chief Operating Officer | Nov 11, 2025 | Sell | $35.10 | 18,932 | $664,513.20 | 12,323 | |
| Stokes Frank | CSTL | Chief Financial Officer | Nov 11, 2025 | Sell | $35.08 | 5,388 | $189,011.04 | 43,328 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Nov 5, 2025 | Sell | $31.85 | 2,678 | $85,296.98 | 45,822 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Nov 4, 2025 | Sell | $30.77 | 6,695 | $203,781.88 | 45,822 | |
| Oelschlager Kristen M | CSTL | Chief Operating Officer | Oct 31, 2025 | Sell | $25.04 | 12,678 | $317,457.12 | 12,323 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
Compare CSTL vs Leading Stocks
See how CSTL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.